Navigation Links
Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results
Date:3/7/2012

ayment due to Par for the successful completion of the second DIFICID Phase 3 trial. Research and development expense for the fourth quarter of 2011 was $14.0 million, compared to $6.9 million for the fourth quarter of 2010. The increase was related to higher health economics and outcomes research as well as medical affairs expenses, DIFICID life cycle management planning, and preparation for a pediatric clinical trial.

For the fiscal year 2011, Optimer reported net income of $7.8 million, or $0.17 per share on both a basic and diluted basis, as compared to a net loss for the fiscal year of 2010 of $47.3 million, or ($1.25) per share on both a basic and diluted basis.  

Net income for the fourth quarter of 2011 was $13.4 million, or $0.29 and $0.28 per share on a basic and diluted basis, respectively, as compared to a net loss for the fourth quarter of 2010 of $11.9 million, or ($0.31) per share, on both a basic and diluted basis.  

As of December 31, 2011, Optimer held cash, cash equivalents and short-term investments of $110.6 million and had 46,689,951 shares outstanding.

2012 DIFICID Launch UpdateBetween January 1, 2012 and February 29, 2012, Optimer estimates approximately $11.0 million in DIFICID gross sales, representing 3,931 DIFICID treatments shipped to wholesalers.

Additionally, as of February 29, 2012:

  • Inventory levels at wholesalers remain within the range of 14 to 28 days of demand
  • Approximately 1,400 hospitals had ordered DIFICID
  • About 65% of hospitals covered by Optimer have reordered DIFICID
  • More than 600 hospitals are estimated to have placed DIFICID on formulary

  • Optimer 2011 and Recent Highlights

  • In December 2011, the EMA granted European marketing approval for DIFICLIR™ (fidaxomicin) tablets.
  • In October 2011, Optimer established a Canadian subs
    '/>"/>

  • SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
    2. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
    3. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
    4. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    5. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    6. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
    7. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
    8. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
    9. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
    10. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
    11. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... 2014 Endo International plc (NASDAQ: ... revenues of $719 million, an increase of 1 percent ... Endo reported net income of $21 million in the ... million in the second quarter of 2013.  As detailed ... for the three months ended June 30, 2014 increased by ...
    (Date:7/31/2014)... July 31, 2014 Marken announced today the ... to meet the clinical trial logistics growth in Central ... expanded facility will continue to serve as a regional ... and from the region, and will provide additional storage ... will combine its office and warehouse into a single ...
    (Date:7/31/2014)... , 31 juli 2014 De Pfizer ... een rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor ... gevestigde PCRU is één van twee onderzoekseenheden ... als ideaal levens te verbeteren door de ontdekking en ... de PCRU op zoek naar mannen en vrouwen van ...
    Breaking Medicine Technology:Endo Reports Second Quarter Financial Results 2Endo Reports Second Quarter Financial Results 3Endo Reports Second Quarter Financial Results 4Endo Reports Second Quarter Financial Results 5Endo Reports Second Quarter Financial Results 6Endo Reports Second Quarter Financial Results 7Endo Reports Second Quarter Financial Results 8Endo Reports Second Quarter Financial Results 9Endo Reports Second Quarter Financial Results 10Endo Reports Second Quarter Financial Results 11Endo Reports Second Quarter Financial Results 12Endo Reports Second Quarter Financial Results 13Endo Reports Second Quarter Financial Results 14Endo Reports Second Quarter Financial Results 15Endo Reports Second Quarter Financial Results 16Endo Reports Second Quarter Financial Results 17Endo Reports Second Quarter Financial Results 18Endo Reports Second Quarter Financial Results 19Endo Reports Second Quarter Financial Results 20Endo Reports Second Quarter Financial Results 21Endo Reports Second Quarter Financial Results 22Endo Reports Second Quarter Financial Results 23Endo Reports Second Quarter Financial Results 24Endo Reports Second Quarter Financial Results 25Endo Reports Second Quarter Financial Results 26Endo Reports Second Quarter Financial Results 27Endo Reports Second Quarter Financial Results 28Endo Reports Second Quarter Financial Results 29Endo Reports Second Quarter Financial Results 30Endo Reports Second Quarter Financial Results 31Endo Reports Second Quarter Financial Results 32Marken Expands Miami Regional Logistics Center 2Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2
    ... Genetic Technologies Limited (ASX: GTG; NASDAQ: ... agreement to jointly develop a new cancer profiling product ... Under the collaboration Genetic Technologies will use ... world-leading pharmaceutical company to develop specific and novel genetic ...
    ... If your medicine has expired, it may not provide ... FDA pharmacist Ilisa Bernstein explains how expiration dates help ... work as intended. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) ... Sign up for e-mail notices of new FDA Consumer ...
    Cached Medicine Technology:GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology 2
    (Date:7/31/2014)... (PRWEB) July 31, 2014 T.E.N., ... relationship-marketing firm, honored finalists and winners Wednesday evening, ... Forum and Awards Gala at the Westin St. ... director of information security for the BlackLine Systems, ... the Year Award winner for the ISE® West ...
    (Date:7/31/2014)... Amy Norton HealthDay ... Babies born with so-called "bubble boy" disease can often be ... -- but early treatment is critical, a new study finds. ... known, actually refers to a group of rare genetic disorders ... at high risk of severe infections. The term "bubble ...
    (Date:7/31/2014)... 31, 2014 (HealthDay News) -- Recovery time after surgery ... known as statins, according to a new study. ... affect the body,s inflammatory response, reducing the amount of ... seemed to be particularly true among people who tend ... of the most widely prescribed medications in the world. ...
    (Date:7/31/2014)... (PRWEB) July 31, 2014 ... to reach $702m by 2020, increasing slowly ... market will be driven by: the rising ... incurred by government agencies, such as Medicare, ... adoption of innovative technologies such as flow ...
    (Date:7/31/2014)... July 31, 2014 -- A new study by researchers ... a peptide called caerulein can convert existing cells in ... diabetes-insulin-producing beta cells. The study, published online July 31 ... new approach to treating the estimated 3 million people ... with type 1 diabetes. , "We have found a ...
    Breaking Medicine News(10 mins):Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 2Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 3Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 5Health News:A new way to generate insulin-producing cells in Type 1 diabetes 2
    ... to be Delayed, CAMBRIDGE, Mass., Nov. 13 ... has received a letter from the U.S.,Food and Drug ... for Synvisc-One(TM) in the United,States. The company now expects ... be delayed in the U.S. until at least the,second ...
    ... to avoid may offer protection , TUESDAY, Nov. 13 (HealthDay ... meats may help improve the chances of surviving a heart ... of a preliminary study in the Nov. 12 online edition ... . , Researchers found that mice fed extra nitrite ...
    ... house,abandoned older pets, who spend their last days watching ... kittens. November is Adopt-a-Senior-Pet Month and is dedicated ... and the fulfillment they can bring to the,right owner. ... these animals have been,surrendered," said Brent Hinton, former Kentucky ...
    ... water work,well for simple cleaning, they won,t do the ... illness. Something stronger must be used. U.S. Nonwovens ... this pressing problem. Rediwipes are proven to kill,99.9 percent ... "The first cardinal rule of safe food preparation in ...
    ... Inc.,(Nasdaq: CLRT ), a premier technology and ... today announced,that it was ranked #19 on Deloitte,s ... was also named to Deloitte,s 2007 Technology Fast ... Fast 50 is a ranking of the 50,fastest ...
    ... - No Human Vaccine Currently Exists Against the ... Deaths in the US so far in 2007;,Collaboration Aims ... as Rapidly as Possible Acambis plc (Acambis) (LSE: ... has signed an exclusive global,collaboration agreement with Sanofi Pasteur, ...
    Cached Medicine News:Health News:Genzyme Receives FDA Response Letter on Synvisc-One(TM) 2Health News:Genzyme Receives FDA Response Letter on Synvisc-One(TM) 3Health News:Nitrite, Nitrate-Rich Foods Boost Heart Attack Outcomes 2Health News:Old Dogs Can Learn New Tricks 2Health News:Disinfecting Rediwipes(TM) Launch Targets E. coli and Salmonella 2Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 2Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 3Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 4Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 5Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 2Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 3Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 4
    Complete cytology platform....
    ... is the first in portability and performance. CTU ... need a flexible, portable system with the state-of-the-art features ... easily to an "E" size tank and has an ... where it is needed.,The CTU Travel Case allows you ...
    The most compact revolutionary innovation in hematology. 26 parameters with 5 Part DIFF...
    ... Total GHb Program separates ... hemoglobin regardless of phenotype ... Schiff Base. Patient results ... DCCT reference to ensure ...
    Medicine Products: